The effect of Curcumin on the prevention of fatty liver caused by tamoxife

Phase 2

Recruiting

• Conditions: Fatty liver caused by tamoxifen in patients with non-metastatic breast cancer.; Malignant neoplasm of breast of unspecified site, female; C50.91

• Registration Number: IRCT20240501061618N1
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 27 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 44

Inclusion Criteria

Women with non-metastatic breast cancer whose pathology is positive in terms of hormone receptors and are treated with tamoxifen.
Normal liver enzymes
Not having viral hepatitis
Not having a history of alcohol consumption
Not using drugs with hepatotoxicity such as methotrexate, amiodarone, valproic acid, anabolic steroids, as well as the use of anticoagulant and antiplatelet drugs.
Insensitivity to curcumin drug
No history of chemotherapy

Exclusion Criteria

The patient's unwillingness to continue the study
Having liver diseases during the study
The use of drugs with hepatotoxicity such as methotrexate, amiodarone, valproic acid, anabolic steroids, as well as the use of anticoagulant and antiplatelet drugs after the start of the study.
Suffering from any related disease and distorting the results during the study
Allergic to curcumin drug
Development of Metastasis during the study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fatty liver grade. Timepoint: 6 months. Method of measurement: Ultrasonography.

Secondary Outcome Measures

Name	Time	Method
iver enzyme level. Timepoint: 6 months. Method of measurement: Lab blood test.